Company profile: DNAe
1.1 - Company Overview
Company description
- Provider of rapid near-patient molecular diagnostics, offering the LiDia-SEQ platform for direct-from-specimen DNA sequencing on a microchip; BSI/AMR test detecting bloodstream infections and antimicrobial resistance from whole blood; a sample preparation system extracting pathogens via immunomagnetic beads; semiconductor sequencing technology; and an oncology program for tumor DNA monitoring.
Products and services
- Semiconductor Sequencing Technology: Silicon transistor–based sequencing detects nucleotides as electrical signals during DNA or RNA sequencing, eliminating fluorescent dyes and precision optics to streamline electrically read detection
- LiDia-SEQ™ Platform: Microchip-integrated, direct-from-specimen system performs DNA sequencing and delivers rapid, actionable information to clinicians from clinical samples
- BSI/AMR Test: Clinical-grade whole-blood assay detects and identifies bloodstream infections and antimicrobial resistance in whole blood specimens, including infections leading to sepsis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DNAe
Rational Vaccines
HQ: United States
Website
- Description: Provider of pre-clinical live-attenuated herpes simplex virus vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rational Vaccines company profile →
Cocrystal Pharma
HQ: United States
Website
- Description: Provider of antiviral therapeutics and candidates, including oral and inhaled PB2 inhibitor CC-42344 for Influenza A (oral: Phase 1 completed, Phase 2 ongoing; inhaled: Phase 1 and 2 completed); preclinical replication inhibitors for Influenza A/B; oral pan-viral protease inhibitor CDI-988 targeting coronavirus and norovirus (preclinical completed, Phase 1 ongoing); and discovery/preclinical pan-viral and norovirus replication inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cocrystal Pharma company profile →
Novexel
HQ: France
Website
- Description: Provider of novel antiinfectives for severe and difficult-to-treat bacterial and fungal infections, engaging in the discovery and development of antibacterial and antifungal agents, supported by an extensive portfolio of compounds, R&D programs, and intellectual property.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novexel company profile →
AiCuris
HQ: Germany
Website
- Description: Provider of resistance breaking antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, hepatitis B and C, and multi-resistant bacteria; offerings include PREVYMIS for CMV prevention in adult CMV-seropositive allogeneic stem cell or kidney transplant recipients, pritelivir (phase 3) for acyclovir-resistant HSV, AIC468 (preclinical) for BK virus, adenovirus treatment programs, and the AiCubator for early-stage research on viral infections in immunocompromised patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCuris company profile →
T2 Biosystems
HQ: United States
Website
- Description: Provider of rapid, accurate infectious disease diagnostics, including the T2Dx Instrument, a fully automated system running tests directly from whole blood, the FDA-cleared T2Bacteria Panel for identifying sepsis-causing bacteria without blood culture, and T2Candida for detecting invasive candidiasis from whole blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T2 Biosystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DNAe
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DNAe
2.2 - Growth funds investing in similar companies to DNAe
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DNAe
4.2 - Public trading comparable groups for DNAe
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →